Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 57,176 shares at $105.67 ($5.9M) on 2023-02-06, disclosed to the SEC on 2023-02-08.
Seasonal sale ($5.9M) by Chief Financial Officer — this insider has traded NBIX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.67 | 1,280 | $135K | 2.3% |
| 2 | $105.67 | 1,280 | $135K | 2.3% |
| 3 | $102.33 | 2,030 | $208K | 3.5% |
| 4 | $102.33 | 2,030 | $208K | 3.5% |
| 5 | $102.40 | 11,491 | $1.2M | 20.1% |
| 6 | $102.40 | 11,491 |
| $1.2M |
| 20.1% |
| 7 | $102.42 | 12,807 | $1.3M | 22.4% |
| 8 | $102.42 | 12,807 | $1.3M | 22.4% |
| 9 | $104.19 | 980 | $102K | 1.7% |
| 10 | $104.19 | 980 | $102K | 1.7% |
| Total | $102.61 avg | 57,176 | $5.9M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |